AC Immune (ACIU) Non-Current Deffered Revenue (2019 - 2026)

AC Immune (ACIU) has reported Non-Current Deffered Revenue for 5 consecutive years, with $106.8 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue rose 113301.19% year-over-year to $106.8 billion; the TTM figure through Mar 2026 stood at $106.8 billion (up 113301.19% YoY), while the FY2025 annual figure was $101.0 billion, up 103882.67% from the prior year.
• Non-Current Deffered Revenue climbed to $106.8 billion in Q1 2026 per ACIU's latest filing, from $104.7 billion in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $106.8 billion in Q1 2026 and bottomed at $94.2 million in Q1 2025.
• Historically, Non-Current Deffered Revenue has averaged $26.5 billion across 3 years, with a median of $100.2 million in 2025.
• Annual changes were most pronounced in 2025 — Non-Current Deffered Revenue rose 5.44% — and 2026, when it jumped 113301.19%.
• AC Immune's Non-Current Deffered Revenue stood at $97.1 million in 2024, then jumped by 107765.77% to $104.7 billion in 2025, then grew by 1.98% to $106.8 billion in 2026.
• Business Quant data shows ACIU's Non-Current Deffered Revenue at $106.8 billion in Q1 2026, $104.7 billion in Q4 2025, and $104.6 million in Q3 2025.